ArticleThe Journal of biological chemistry2026
A signal sequence multi-leucine motif regulates VEGF receptor signaling.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Signal sequences (SS) target newly synthesized proteins to the endoplasmic reticulum and, eventually, the plasma membrane. Discoidin, CUB, and LCCL domain containing 2 (DCBLD2) is a transmembrane protein with an unusually long SS that interacts with vascular endothelial growth factor receptor (VEGFR)-2 and promotes VEGF-induced endothelial cell signaling, proliferation and migration, as well as angiogenesis. How DCBLD2 interacts with VEGFR-2 to modulate VEGF signaling remains unclear. We generated various constructs containing different combinations of DCBLD2 domains, including its SS, and conducted co-immunoprecipitation and signaling studies in HEK 293T and endothelial cells to identify the smallest DCBLD2 unit that interacts with VEGFR-2. Other proteins containing this unit were identified, and their interactions with VEGFR-2 were evaluated. The DCBLD2 SS interacted with VEGFR-2 and promoted VEGF signaling. The smallest unit in the DCBLD2 SS that interacted with VEGFR-2 was the L5VL5 sequence. Even after the central valine was removed, the L10 sequence mimicked the DCBLD2 SS effect on VEGF-signaling, while shorter or longer multi-leucine sequences were less effective. We identified several other human proteins containing such uncleaved multi-leucine SS, including CD45-associated protein (CD45-AP) and BRICHOS domain containing 5 (BRICD5). Both these proteins could interact with VEGFR-2, and CD45-AP could modulate VEGF signaling in endothelial cells. In conclusion, a multi-leucine motif in SS can directly engage in protein-protein interactions and modulate VEGF signaling. These findings refine the traditional view of SS as merely targeting elements, emphasizing their role in cellular signaling and opening new avenues for research and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.